A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial-Reference-Cited by-同舟云学术

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial

Published:2009-09 Issue:9 Volume:25 Page:509-515
ISSN:0828-282X
Container-title:Canadian Journal of Cardiology
language:en
Short-container-title:Canadian Journal of Cardiology

Author:

Bertrand Olivier F.,Poirier Paul,Rodés-Cabau Josep,Rinfret Stéphane,Title Lawrence,Dzavik Vladimir,Natarajan Madhu,Angel Juan,Batalla Nuria,Alméras Natalie,Costerousse Olivier,De Larochellière Robert,Roy Louis,Després Jean-Pierre

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference42 articles.

1. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers;Mudaliar;Ann Rev Med,2001

2. Diabetes mellitus and the cardiovascular system;Nesto,2001

3. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial;Alexander;JAMA,2005

4. Prognostic factors for atherosclerosis progression in saphenous vein grafts. The Postcoronary Artery Bypass Graft (Post-CABG) trial;Domanski;J Am Coll Cardiol,2000

5. Accelerated “atherosclerosis”. A morphologic study of 97 saphenous vein coronary artery bypass grafts;Bulkley;Circulation,1977

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor Alpha and Gamma Agonists on Myocardial Damage: Molecular Mechanisms and Clinical Evidence—A Narrative Review;Cells;2024-09-05

2. The forgotten type 2 diabetes mellitus medicine: rosiglitazone;Diabetology International;2021-06-29

3. Plaque Assessment on Serial Coronary CTA;Current Cardiovascular Imaging Reports;2019-02-14

4. Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1‐year randomized study;Diabetes, Obesity and Metabolism;2018-04-19

5. Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes;Clinical Autonomic Research;2016-08-06